Topical formulations comprising montelukast and combinations with mussel adhesive proteins
AssigneeEnlitisa (Shanghai) Pharmaceutical Co., Ltd.
InventorsBengt Ingemar SAMUELSSON, Ming GU
Life of this patent
Estimating the term…
Abstract
There is provided topical pharmaceutical formulations comprising montelukast, or a pharmaceutical acceptable salt of solvate thereof, as well as combination products comprising (a) at least one mussel adhesive protein or a derivative thereof; and (b) montelukast, or a pharmaceutically-acceptable salt or solvate thereof. The formulations and combination products find particular utility in direct topical administration for the treatment of inflammation, of inflammatory disorders and/or of condition characterized by inflammation, including wounds, burns, psoriasis, acne and atopic dermatitis.
Claims14
1-26. (canceled)
A method of promoting healing or recovery of a wound of a patient, said wound being an ulcer of the skin or the mucosa, the method comprising:
- providing a pharmaceutical formulation that is in the form of a gel, a cream or an ointment and comprises a therapeutically effective amount of montelukast, or a pharmaceutically acceptable salt of solvate thereof, in admixture with a pharmaceutically-acceptable topical adjuvant, diluent, or carrier;
- topically applying the pharmaceutical formulation directly to an ulcer wound of a patient,
- wherein the ulcer wound comprises injury to the skin or mucosa, damage to and/or below the epidermis or the dermis, or damage to a subcutaneous tissue, a submucosal tissue, or an internal organ, and
- wherein said topically applying promotes healing or recovery of the ulcer wound.
Dependencies are inferred from the claim text.